ArticleAnnals of transplantation2017
Expression and Clinical Significance of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and a Disintegrin and Metalloproteinase with Thrombospondin Type 1 Motif 1 (ADAMTS1) in Post-Kidney-Transplant Bladder Tumors.
Article in Annals of transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND To investigate the expression and clinical significance of tissue inhibitor of metalloproteinases-1 (TIMP-1) and a disintegrin and metalloproteinase with thrombospondin type 1 motif 1 (ADAMTS1) in post-kidney-transplant bladder tumors. MATERIAL AND METHODS A total of 27 patients with new bladder tumors occurring after surgical kidney transplants (the experimental group) and 56 patients with conventional new bladder tumors (the control group) were included in this study. All the patients were confirmed to have transitional cell carcinomas by postoperative pathological examination. Fifteen pairs of new bladder tumor specimens (from each of the 2 groups) were selected and subjected to whole-genome oligonucleotide microarray screening to determine the differences in gene expression profiles and analysis using the biomolecule annotation system. Subsequently, quantitative real-time polymerase chain reaction (qRT-PCR), immunohistochemistry, and Western blot analysis were performed to determine and compare differences in the expression of TIMP-l and ADAMTS1 in the urothelial tumors of the 2 groups. RESULTS Analysis of co-differentially expressed genes showed 23 groups of pathways with significant differences (P<0.05) and included immunosuppression and tumor development and progression. TIMP-l expression was significantly higher in the experimental group than in the control group, whereas ADAMTS1 expression was significantly lower in the experimental group than in the control group (P<0.05). CONCLUSIONS Significant differences in gene expression profiles were observed between patients with post-kidney transplant bladder tumors and those with conventional bladder tumors, and the expression of TIMP-1 and ADAMTS1 has important significance for the diagnosis of post-kidney-transplant bladder tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.